Transactions
Desitin Arzneimittel GmbH licensed U.S. rights to Oxcarbazepine MR to Jazz Pharmaceuticals
Jul. 2005
Client: Desitin Arzneimittel GmbH is a leading developer and marketer in selected European countries of central nervous system (CNS) prescription pharmaceuticals
Role: Edgemont Partners acted as exclusive financial advisor to Desitin Arzneimittel GmbH in its partnering of exclusive U.S. rights to its development stage product Oxcarbazepine MR to Jazz Pharmaceuticals
Location: Hamburg, Germany
Sector: Pharmaceutical Services
Lead Banker: David Blume
licensed U.S. rights to Oxcarbazepine MR to
